Enterovirus 71 (EV71) is a common pathogen responsible for hand, foot, and mouth disease (HFMD), leading to severe neurological complications and even death. However, the mechanisms underlying severe EV71-induced disease remain unclear, and no effective specific treatments are available. In this study, we successfully infected mice of different ages using a mouse-adapted EV71 strain, resulting in disease and mortality. We compared immune system responses between infected and uninfected mice of different ages to identify key pathogenic targets during EV71 infection. Our findings revealed that the level of Group 3 Innate Lymphoid Cells (ILC3s) in mice negatively correlated with the severity of disease induced by EV71 infection. We conducted anti-ILC3 cytokine injections and cytokine neutralizing antibody experiments on 14-day-old EV71-infected mice. The results showed that the cytokine IL-17 secreted by ILC3 cells had a mild protective effect, while IL-22 promoted inflammatory responses. Our research demonstrates that ILC3 cells play a dual role in EV71 infection. These findings not only clarify key immune factors in the progression of EV71-induced disease but also provide a promising approach for the early diagnosis and treatment of severe EV71 infections.
31 December 2023 in Cellular and Molecular Biology
Hand, foot, and mouth disease (HFMD) can cause fatal encephalitis in 0-5-year-old infants and children. There is no effective antiviral drug available to treat HFMD caused by enterovirus 71 (EV71). Our study investigates the relationship between levels of IL-22 expression and the severity of disease after EV71 infection in a mouse model. Anti-IL-22 neutralizing antibodies were tested in EV71-infected mice of different ages. Our results show that anti-IL-22 neutralizing antibodies can effectively reduce mortality in EV71-infected mice. Anti-IL-22 neutralizing antibody effectively reduced various EV71-associated symptoms indicating promising potential of this therapeutic effector in patients with EV71-associated HFMD.
Colorectal ovarian metastasis (CROM), a distinct metastatic subtype of colorectal cancer, is associated with early disease onset and aggressive progression. CROM lacks specific treatment options, highlighting the need to elucidate the underlying biological mechanisms and potential therapeutic vulnerabilities. In this study, we performed integrated analyses of single-cell RNA sequencing (scRNA-seq) datasets from 155,163 cells across 35 patients from the in-house cohort and public datasets, with matched bulk transcriptomic profiling. The analysis identified AKT3+ epithelial–mesenchymal transition (EMT)-like cells at the invasive tumor–stroma interface as metastasis-initiating cells. Functional validation using in vivo xenograft models demonstrated that AKT3 deficiency reduced ovarian colonization, whereas AKT3 overexpression conferred a mesenchymal phenotype with invasive capacity. Furthermore, reciprocal cross-talk between AKT3+ mesenchymal-like cells and cancer-associated fibroblasts (CAF) played a key role in remodeling the tumor microenvironment. Multiplex immunofluorescence staining of primary tumor specimens revealed spatially coordinated AKT3+/SNAIL+/ITGB1+ tumor buds adjacent to αSMA+ CAFs at the invasive front. Critically, AKT3 inhibition or knockdown in patient-derived CROM organoids (CROM-PDO) significantly suppressed malignant phenotypes, recapitulating the AKT3 dependency. Collectively, these findings elucidate an AKT3-driven feedforward loop coupling EMT plasticity with CAF activation as a critical driver of CROM and propose CROM-PDOs as a robust platform for developing precision therapies targeting this aggressive colorectal cancer subtype. Significance: Single-cell analyses reveal AKT3-expressing mesenchymal-like cells as drivers of colorectal ovarian metastases, which depends on the dynamic cross-talk between cancer cells and cancer-associated fibroblasts within the immunosuppressive ovarian niche.